Ceruvia Lifesciences
Ceruvia Lifesciences is a US-based clinical-stage biopharmaceutical company founded in 2017 by philanthropist Carey Turnbull, focused on developing neurotransformational medicines for neurological and psychiatric disorders. The company was the world's first producer of cGMP-certified LSD and its non-hallucinogenic analogue BOL-148. Ceruvia is advancing SYNP-101 (synthetic psilocybin) through Phase 2 trials for OCD, alcohol use disorder, and migraine/headache disorders, and NYPRG-101 (BOL-148) for cluster headache. Collaborators include Yale University, the Heffter Research Institute, Usona Institute, NYU, and Clusterbusters.
Drug Pipeline
4SYNP-101
PsilocybinObsessive-compulsive disorder (OCD). Synthetic psilocybin. FDA IND cleared. Phase 2 multicenter, randomised, double-blind, active placebo-controlled study; single oral dose, primary endpoint: Y-BOCS reduction at 12 weeks. Pilot Phase 2 data from Yale showed rapid and durable OCD symptom improvement.
SYNP-101
PsilocybinAlcohol use disorder (AUD). Synthetic psilocybin. Phase 2 IND submitted; trial to start. Conducted in collaboration with Yale University.
SYNP-101
PsilocybinMigraine headache prevention. Synthetic psilocybin. Phase 2 programme, IND filed.
NYPRG-101 (BOL-148)
LSDCluster headache. BOL-148 is a non-hallucinogenic analogue of LSD first synthesised at Sandoz by Albert Hofmann (1957). Ceruvia holds a Harvard patent licence for BOL-148 in cluster headache. Safely administered clinically to ~300 people. Phase 1/2 development stage.
Quick Facts
- Type
- Private Biotech
- Founded
- 2017
- Lead Stage
- Phase II
- HQ
- USA, United States
- Website
- Visit